Material Mapper’s vision is to create a market of scale for secondary building materials by mapping them in Europe and leading the transition towards a closed-loop circular construction and demolition industry. The European construction industry is urgently lacking clear, centralized access to information about secondary building materials available in their area, due to the fragmentation and inconsistency with which these public data are captured and stored. This makes building planning with quality secondary building materials time and cost-intensive for stakeholders, in turn making it difficult to comply with the EU’s Waste Directive of 70% recycled/re-used building materials. Our young, multi-award-winning company is planning to launch a project over 24 months to build a breakthrough innovation for the whole of Europe using artificial intelligence and machine learning that will extract, read, evaluate, and forecast quantities of secondary building materials for the user, making future planning for property developers seamless through our platform. We are confident that our product is unique and that we have no direct competition. By combining our deep technology, partnership development, and B2B sales expertise, we are already working closely with major industry actors to harness insights and their existing networks for our customer base.

Participant of Equinor & Techstar Energy Accelerator 2023 🚀 🌱We believe in the power of managing human skills for solving real problems, by elevating our capabilities and our mindset. WeMe is a Norwegian Wellbeing Tech Startup developing AI-based SaaS tools for employees and managers that empowers businesses to integrate wellbeing through action based digital dialogue, preventing stress and burnout and improving overall performance. - Easy to implement and offering great value with immediate results improving mental and emotional health. Because Dialog Pays Off.

Coming from all over the world, our IKEA co-workers share a special set of values and a vision to enable people to live a better, more sustainable everyday life. They come together within diverse, inclusive, open IKEA work environments, where each of them offers something unique. WHY YOU WILL LOVE US From the deep forests in Sweden, we have spread our culture and values around the world. At the heart of our offer are our beautiful home-furnishing products and solutions, made with care for our planet, reaching millions of customers. At the heart of our business, are our wonderful co-workers representing diversity in all dimen­sions and passion for life at home. We all contribute with our uniqueness and we want to grow and develop together. Our vision, “to create a better everyday life for many people” inspires and guides us in everything we do. This is IKEA. WHAT WE ALL HAVE IN COMMON Living our values Being your unique self, while respecting and including others A passion for home furnishingPerforming & delivering while learning & developing Having fun!

Apprend.ly is a platform for creating educational 3D games. It is intentionally made user-friendly and requires no technical background to use. Games made with Apprend.ly can be streamed directly from any device, making them accessible to anyone with an internet connection. We believe that interactive e-learning is the next step in the evolution of education, succeeding one-way communication methods such as videos and presentations.

Octo Ventures, based in Oslo, Norway, is an incubator that initiates, invests in, and develops companies together with external co-founders. Based on investment criteria that have proved to deliver superior returns, we have developed a proprietary algorithm that generates high-potential ideas. Our methodology combines best practices within innovation, product development, and business design to accelerate the process from concept development to MVP and commercial launch.

Novelty Food was established to promote great-tasting gifts for the premium market. Our basic philosophy is to create products that are tempting enough for you to buy the first time, and tasty enough for you to want to buy again. Novelty Food er et utviklings-, salgs, og markedsselskap for premium produkter. Vi har en stabil og god salgsbase i Norge med salg til både Norgesgruppen, Sunkost og Tax Free butikkene. Vi har i tillegg flere internasjonale partnere – blant annet Disney World og EPCOT, hvor Grieg Suites er valgt som den norske sjokoladen for salg.

Migraine is an underdiagnosed and undertreated brain disease. 1 in 7 people worldwide is affected by migraine. Nordic Brain Tech develops a treatment that is home-based and self-administered. The invention has gotten worldwide attention from key opinion leaders within migraine. There is a huge market need, and a willingness to pay for the product from both hospitals and migraine patients.

Approximately 50% of Norwegians sell their car to a car dealer. With Nettbils managed marketplace car sellers get offers from 850+ dealers and sell their cars without after-sale risk in less than a workday. - 23% MoM growth since the last investment round in April 2018. - Great customer ratings and case studies from car sellers and car dealerships - First mover advantage in the Norwegian market and currently 1% market share - Easily scalable with NAF and Viking as partners - Own unique custom made tech-platform - With partnership, Nettbil can establish the product in Finland and Denmark

Radiocrafts is a leading RF module design and manufacturing company. Radiocrafts’ standard RF modules provide compact, easy-to-use, low cost, low power and high performance RF solutions for a large number of wireless applications using license-free ISM bands. By using modules OEM manufacturers without RF design knowledge can easily add wireless technology into their design, reducing time-to-market, cost of design, test, and compliance approvals. Radiocrafts also offers custom and application-specific product development, supporting customers from initial project ideas to volume product delivery. Radiocrafts currently provides solutions in the frequency bands 169, 433, 868, 915, and 2450 MHz, supporting radio protocols such as Wireless M-Bus, KNX, ZigBee, 6LoWPAN, SIGFOX, WIZE as well as proprietary solutions such as TinyMesh, RC232, and now our newest product lines, RIIoT and RIIM.

Revolusjonen er i gang! Verden endrer seg i et forrykende tempo. Innovasjon og stadig fornyelse er viktigere enn noen gang for å beholde kundene. Moderne teknologi har raskere enn noensinne gjort at IT flytter seg nærmere forretning. Nå må beslutninger tas raskt og «fail fast» er nøkkelord. Revolusjonen har såvidt begynt og i Aboveit forstår vi effekten, virkemidlene og veien til målet.   Aboveit bygger broen mellom teknologi og forretning  - Ved å ta i bruk skyens kapabiliteter hjelper vi deg med å realisere forretningsverdi og å skape fortrinn i markedet. Vi er sikre på at morgendagens vinnere er de som får mest ut av plattformene og tjenestene i skyen. Vår tilnærming til transformasjon og digitalisering vil endre måten våre kunder tenker på sky. Vi er klare for reisen og til å løfte våre kunder til nye høyder. Velkommen til Aboveit - Vi kan hjelpe deg!

Versiro develops software that accelerates the energy transition. Renewable electricity is great for the environment but difficult to plan because its production depends on uncertain weather conditions. Versiro develops an AI copilot that helps renewable producers make smart decisions in real time while considering these uncertainties. This assists the integration of renewable energy and increases its profitability, two key factors to enable the green energy transition. Versiro was founded by researchers at the Norwegian University of Science and Technology (NTNU) and follows the observation that, in electric power systems, the traditional pipelines from research to industry are too outdated to keep up with the fast-paced world of machine learning.

Biozep is discovering and developing first-in-class drug products for the treatment of severe eye diseases which can lead to vision loss and where it is a high unmet medical need. Biozep has discovered novel drug substances based on bioactive lipids which modulate central pathways involved in the pathogenesis of eye diseases. Targets and biomarkers are identified based on a system biology approach combined with in-depth knowledge about bioactive lipids, their endogenous synthesis and mechanisms of action. Biozep has made a prototype drug product based on our lead compound for topical administration and the product will be tested in animal models in 2018. Our goal is to start clinical studies in 2020. Biozep is a company depending on both internal and external resources. Biozep has established its own laboratory in Oslo in order to do synthesis, purification, quality control and chemical development in-house. The biological testing of the drug substances is performed in collaboration with carefully selected contract research organizations both in Europe and the USA. In order to reach the market as fast as possible and to reduce risk, Biozep will seek strategic partnerships early in the drug development phase. Biozep seeks partners with complementary competence and with resources to conduct clinical trials and with market access. We are already in dialogue with potential partners and hope to sign an agreement in 2018-19.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

LangO is changing the way companies deliver English language training to their employees online. We do this through a blended learning solution; a combination of live virtual lessons (Group Live Lessons and One-to-One) complemented by our on-demand micro-learning activities. Our responsive web app brings in the best-qualified teachers from around the world, custom-made LangO lesson content based on client's needs, and a scalable tech stack enabling employees to learn effectively on any device, at any time.

BRIK as is a company specialising in new web technology, pedagogy and professional dissemination of knowledge. The team has extensive experience in the dissemination of knowledge with new web technologies and video. Our investors and partners are Innovation Norway, the Norwegian Research Council and several customer partners. The budget for the initial development phase (2013 - ) has been 12 MNOK. Now we are looking for partners for the next stage, where we will commercialize and increase sales.